Company intelligence / Profile preview

Bharat Medica

Hyderabad, Telangana, Indiabharatmedica.com ↗

Ownership: Private
Development stage: Commercial

Overview

Bharat Biotech has developed over 19 vaccines and four biotherapeutics with global registrations in over 125 countries. Notable achievements include the world's first tetanus-toxoid conjugated typhoid vaccine, successful Phase III trials of oral cholera vaccine Hillchol in May 2025, and large-scale COVID‑19 vaccine production. Over nine billion doses delivered worldwide as of May 2025.[1][2]

Therapeutic areas: EndocrinologyDermatologyInfectious Diseases
Modalities: VaccineBiologicSmall moleculeRecombinant protein
Industry: Biotech

Partnerships

GSK (Shigella vaccine candidate licensed from GSK to Bharat Biotech)Department of Science & Technology India / Indian Institute of Science Bangalore collaboration on hepatitis B vaccine development

Beyond the preview

Go deeper on Bharat Medica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bharat Medica.

Explore the full profile